Bristol-Myers Squibb Patient Assistance Foundation Inc.

Bristol-Myers Squibb Patient Assistance Foundation Inc. (BMSPAF) occupies a category entirely apart from traditional philanthropic foundations. It does not award grants to nonprofit organizations, academic institutions, or government agencies. Its sole beneficiaries are individual patients who cannot afford BMS prescription medications and who fall outside existing insurance and government pharmacy coverage systems. Understanding this distinction is essential before investing any time in an application.

BMSPAF was incorporated in April 1999 as a corporate operating foundation (IRS foundation code 03) headquartered in Princeton, NJ. All contributions flow from Bristol-Myers Squibb, and all disbursements go to what the foundation classifies on its 990 as 'Individual Patient Programs.' There are no competitive grant cycles, no institutional LOI requirements, no board selection rounds. Applications are evaluated on a rolling basis against objective eligibility criteria.

The foundation's giving philosophy is access to medication as a basic necessity. Eligible patients must clear two hard gates: absence of private prescription drug coverage and ineligibility for Medicaid or equivalent government pharmacy benefits. Medicare patients face an additional means test — they must document that out-of-pocket prescription costs equal at least 3% of annual household income. Income limits are means-tested rather than expressed as fixed dollar thresholds, which means applicants who self-screen out based on assumptions about income cutoffs may be leaving significant value on the table.

For organizations serving underinsured or uninsured populations — federally qualified health centers, community health workers, cancer resource centers, hospital social work departments, and patient advocacy nonprofits — the most strategic posture is not to seek BMSPAF as an institutional funder but to train staff in BMSPAF eligibility screening and application navigation as a patient benefit service. Experienced navigators who submit BMSPAF applications regularly understand what reviewers flag and can move eligible patients into coverage far faster than first-time applicants. The retail value of medications received — often $3,000 to $15,000 or more annually per patient for branded biologics like Orencia or Eliquis — makes BMSPAF one of the highest-value patient assistance programs available for its covered drug portfolio.

BMSPAF's financial profile is unlike any traditional foundation of comparable asset size. With $230.7 million in total assets (FY2024), it would appear modest by conventional standards — but its annual giving dwarfs asset-comparable peers by a factor of 100x or more. This is because BMSPAF is a pure pass-through corporate foundation: Bristol-Myers Squibb contributes cash or drug value annually, and the foundation immediately distributes it as pharmaceutical grants to individual patients. Its assets function as operating reserves, not endowment; investment income across all reported years is $0.

Giving has grown dramatically over the past decade. In FY2012, grants paid totaled $548.9 million. After a modest dip in FY2015 ($619.6 million), growth resumed strongly: $1.28 billion (FY2019), $1.46 billion (FY2020), $1.77 billion (FY2021), $2.86 billion (FY2022), and a peak of $4.39 billion in FY2023, with total giving (including non-cash) reaching $4.46 billion. FY2024 saw a significant decline: revenue fell to $2.72 billion — a 38.9% drop from FY2023 — coinciding with Revlimid's (lenalidomide) loss of exclusivity in 2022 and its subsequent transition off the BMSPAF covered drug list.

All giving flows to one recipient type: Individual Patient Programs. The two largest discrete recorded disbursements total $7.25 billion, averaging $3.6 billion each — reflecting the enormous throughput of distributing pharmaceutical products at scale. A separate analysis citing FY2023 data counts approximately 287 discrete grant batches averaging $15.3 million each, suggesting that individual patient cohorts are tracked by program and period rather than as single patient-level transactions.

Officer compensation across all reported years is $0. The foundation employs no paid staff. Revenue is 100% from contributions received — exclusively from BMS. These characteristics make BMSPAF's financial sustainability entirely dependent on BMS corporate health and its branded specialty drug portfolio. As BMS launches new specialty medications, expect BMSPAF's covered drug list and giving volume to expand; as drugs face generic competition, expect covered volume to shift or decline.

The database identifies peer foundations by asset size within the Human Services NTEE category. The comparison below reveals BMSPAF's structural distinctiveness:

Note: Peer annual giving figures are estimates using typical 4–8% endowment payout ratios; BMSPAF's giving is driven entirely by annual BMS corporate contributions, not by asset returns.

The comparison exposes a fundamental structural difference. Asset-comparable peers are endowed philanthropies that give $5–20 million annually — modest but predictable institutional grantmakers. BMSPAF gives $2–4 billion annually because it is a corporate pass-through vehicle receiving annual contributions from one of the world's largest pharmaceutical companies. Organizations seeking institutional grants should engage peers like Callaway Foundation or Illinois Children's Healthcare Foundation. BMSPAF's resources flow exclusively to individual patients receiving free medications — a resource stream measured in therapeutic value, not grant checks to organizations.

The most significant recent development in the BMS philanthropic ecosystem is the October 2025 announcement of a $1 million donation from the Bristol Myers Squibb Foundation — BMSPAF's sister entity — to the Patient Advocate Foundation. The gift, made during BMS's Global Patient Week 2025 (an annual company-wide event honoring patients), funds expansion of PAF's nationally recognized case management program that helps seriously ill patients navigate insurance and financial barriers. While this grant came from the BMS Foundation rather than BMSPAF, it signals that the broader BMS philanthropic enterprise is investing in patient navigation infrastructure in 2025–2026 — infrastructure that frequently connects patients to BMSPAF.

On BMSPAF's own operational side, updated enrollment forms for Eliquis, Nulojix, Orencia, and Sotyktu were published in October 2025, confirming active program continuation through the 2026 coverage year.

Financially, FY2024 marked a significant contraction: revenues fell 38.9% from FY2023's $4.46 billion peak to approximately $2.72 billion — reflecting the post-Revlimid portfolio restructuring rather than any program discontinuation. Leadership has been stable across all reporting years: John L. Damonti serves as President and Chairman without compensation. Governance changes in December 2022 added Felecia Ettenberg as Secretary and Tim Kocses as Treasurer, replacing departing officers. The foundation maintains zero paid employees and is governed entirely by BMS corporate officers serving pro bono.

The single most important step before beginning any BMSPAF application is drug verification. As of 2025–2026, BMSPAF covers exactly five BMS medications: Eliquis (apixaban, anticoagulant), Orencia (abatacept, rheumatoid arthritis), Sotyktu (deucravacitinib, plaque psoriasis), Zeposia (ozanimod, ulcerative colitis and multiple sclerosis), and Nulojix (belatacept, kidney transplant rejection prophylaxis). If the patient's BMS prescription is not on this list, BMSPAF is the wrong door — direct them to BMS Access Support at bmsaccesssupport.com for oncology medications including Opdivo and Yervoy.

For covered medications, the eligibility screen operates on three hard gates that must be confirmed before beginning paperwork. First, the patient must have no private prescription drug insurance coverage. Second, the patient must be ineligible for Medicaid, CHIP, or equivalent government pharmacy benefits. Third, income must fall within BMSPAF's means-tested thresholds — which the foundation does not publish as fixed dollar limits, so do not pre-screen patients out based on assumptions. Medicare beneficiaries face a fourth requirement: they must document that annual out-of-pocket prescription costs equal at least 3% of household income. This is the most frequently misunderstood eligibility criterion; gather 12 months of pharmacy receipts or Medicare Part D explanation-of-benefits statements before submitting.

Income documentation strategy matters. Federal tax returns provide the most complete income picture and tend to process fastest. If a recent return is unavailable, 1099 forms, Social Security award letters, pension statements, or two consecutive recent pay stubs are acceptable substitutes — but using multiple incomplete documents increases review time.

The application is available at bmspaf.org/apply and requires completion by both the patient and their prescribing physician. Physician signatures are mandatory; applications missing clinical attestation are returned without action. In practice, experienced patient navigators batch physician co-signature requests to reduce administrative friction.

Submit by fax (800-736-1611) for fastest processing. Mail to PO Box 220769, Charlotte, NC 28222-0769. BMSPAF assistance is approved for defined periods, not permanently — set renewal reminders 60 days before coverage ends to avoid gaps in therapy for patients on chronic medications.